On May 24, 2023 Excyte Biopharma reported its YK012 (CD3), a bispecific antibody drug, was used for the treatment of recurrent/refractory B-cell non Hodgkin’s lymphoma × CD19) Phase I clinical study completed the first drug administration in Phase I ward of Chinese Academy of Medical Sciences Cancer Hospital (Press release, Excyte Biopharma, MAY 24, 2023, View Source;lang=en [SID1234646276]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At 9:40 am on the same day, YK012 injection slowly flowed into the subject’s body through a micro injection pump and infusion pipeline. After 24 hours of administration, the subject had no adverse reactions and was in stable condition. In order to ensure the safety of the subjects and collect safety data of this product, the research team is closely monitoring the treatment response of the subjects and will promptly share information with all parties involved in the project.
Under the full promotion of the project team of the company, contract research organization Beijing New Leading Medicine and the Cancer Hospital of the Chinese Academy of Medical Sciences worked together to complete the first drug administration 17 days after the project kick-off meeting, highlighting the "speed of Yikesite". Yike Si Te is making every effort to rapidly advance the clinical progress of YK012, complete the product launch as soon as possible, and enable more patients to use the new drug as soon as possible, solve their pain, and improve their quality of life.
YK012 developed by Yikesite has a similar mechanism of action to Amgen’s Beretol, but it is significantly superior to Beretol in terms of molecular structure, half-life, production level and toxicity. Preclinical studies have shown that YK012 may have better clinical efficacy and safety, and is expected to provide better treatment options for refractory and recurrent ALL and NHL. In addition, through clinical trial exploration, it is possible to expand YK012 to more indications.
Yikesite (Beijing) Pharmaceutical Technology Development Co., Ltd. was jointly founded by Dr. Yuan Qing’an and Mr. Meng Qingwu, who came back from a famous American pharmaceutical company. The company makes full use of the founder’s years of experience, technical advantages and team strength to develop innovative bispecific antibody drugs for blood cancer, multiple myeloma, triple negative breast cancer and liver cancer. These projects have the characteristics of long-term, low toxicity, and high-yield technological innovation, and are positioned as the best or first of their kind. I believe that with the progress of the product pipeline, the company will have more dual antibody varieties entering the clinical stage, providing better treatment methods for patients.